NRx Pharmaceuticals (NASDAQ:NRXP) moved a step closer to commercializing its generic preservative-free ketamine today, announcing that the FDA’s Office of Generic Drugs has provided preliminary alignment on the product's labeling.
The communication from the FDA indicates that previous label comments were limited to minor formatting adjustments, signaling that the technical and clinical hurdles for the Abbreviated New Drug Application (ANDA) have largely been cleared.
NRx Pharmaceuticals confirmed it expects to submit the final version of the label within the month, setting the stage for a formal GDUFA (Generic Drug User Fee Amendments) decision expected in Summer 2026.
The announcement follows a prior preliminary determination of bioequivalence, a critical regulatory benchmark confirming that the NRx formulation performs the same as the brand-name reference drug.
While the labeling remains subject to a final supervisory review by the agency, the "preliminary alignment" is typically viewed by industry analysts as a high-probability indicator of an upcoming approval.
NRx has positioned this launch as a strategic response to ongoing domestic supply chain vulnerabilities.
The company emphasized that its ketamine is entirely U.S.-manufactured, which could provide a stable alternative to foreign-sourced supply during the current nationwide backorders for the anesthetic.
Preservative-free ketamine is frequently utilized in specialized clinical settings, including pediatrics and neurology, where additives found in standard formulations may be contraindicated.